Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

It's rare these days for an artist to ask for fewer microphones, but after warming up in our space, Billy Strings did just that. Surrounded by his band, the bluegrass virtuoso brings back the spirit ...

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Chris Wedel is a fan of all things tech and gadgets. Living in rural Kansas with his wife and two young boys makes finding ways to stay online tricky — not to mention making my homestead smarter.

Lando Norris, Max Verstappen and Oscar Piastri are set for an epic Formula 1 title decider on Sunday, with Verstappen on pole for the Abu Dhabi Grand Prix. Verstappen, after taking advantage of a ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After strategy drama in Qatar, Norris is 12 points ahead of Verstappen and 16 points in front of McLaren team-mate Piastri with 25 points for a win in Sunday's race at the Yas Marina Circuit.